• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Landiolol effective at controlling heart rate in sepsis related tachyarrhythmias

byAlex ChanandRavi Shah, MD MBA
April 13, 2020
in Cardiology, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Postoperative and nonoperative atrial fibrillation have a similar risk of associated thromboembolism

Sleep disorders and insomnia may be strongly associated with atrial fibrillation

Wellness Check: Sleep

1. Landiolol administration resulted in significantly more patients achieving target heart rates of 60-94 following sepsis-related tachyarrhythmia and was also associated with significantly reduced incidence of new onset arrhythmia

Evidence Rating: 1 (Excellent)

Sepsis associated tachyarrhythmias and atrial fibrillation are significant causes of mortality, with as many as a third of patients reaching fatal outcomes. In the context of sepsis, treatments traditionally used for tachyarrhythmias are often ineffective or contraindicated, leading to a small selection of effective treatment strategies. Retrospective studies have shown landiolol, an ultra-short-acting β1-blocker to be an effective rate control agent in the context of sepsis-related tachyarrhythmias, but no randomized controlled trials have been completed to further investigate its efficacy and safety. In this multicenter, open-label randomized controlled trial, 151 patients admitted to 54 different hospitals in Japan between 2018 to 2019 were recruited to address this knowledge gap. Patients included were 20 years of age or older, had been diagnosed with sepsis according to Third International Consensus Definitions for Sepsis and Septic Shock, and had developed either sinus tachycardia, atrial fibrillation, or atrial flutter without a change in catecholamine dose. Seventy-five patients were randomized to the standard therapy group (including respiratory and fluid resuscitation, antimicrobials, and catecholamines), and 76 to the treatment group, consisting of standard therapy and landiolol hydrochloride infusion at 1 μg/kg per min within 2h after randomization, with an option to increase the dose per study protocol to a maximum of 20 μg/kg per min. Compared to the control group, the group receiving landiolol had a significantly greater proportion of patients achieving target heart rate (60-94BPM) at 24 hours post randomization (55% versus 33%, between-group difference, 23.1%, 95% CI 7.1-37.5; p=.0031), with effects maintained until the end of the 96 hour treatment period. New-onset arrhythmia over 168 hours post randomization was also lower in the landiolol group that controls. landiolol appeared to be well tolerated in the treatment group, though few patients were reported to experience hypotension (4%), cardiac arrest (1%), bradycardia (1%), and reduction in ejection fraction (1%). This study represents the first randomized controlled trial investigating landiolol for administration in sepsis-related tachyarrhythmias, and evidence seems to support prior literature for the drug as an effective rate control agent.

Click to read the study in Lancet Respiratory Medicine

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: atrial fibrillationatrial flutterbeta antagonistlaniololtachyarrhythmias
Previous Post

COVID-19 patients with coagulation dysfunction may benefit from prophylactic anticoagulation

Next Post

Clinical and epidemiologic features of COVID-19 in children

RelatedReports

Radiofrequency catheter ablation effective as first-line therapy for atrial fibrillation [RAAFT-2 trial]
Cardiology

Postoperative and nonoperative atrial fibrillation have a similar risk of associated thromboembolism

August 11, 2022
β-blockers linked to improved survival in preserved ejection fraction heart failure
Cardiology

Sleep disorders and insomnia may be strongly associated with atrial fibrillation

July 11, 2022
Decline in adolescent sleep duration over past 20 years
Wellness

Wellness Check: Sleep

July 7, 2022
#VisualAbstract: New-onset atrial fibrillation following hospitalization for pneumonia associated with increased thromboembolic risk
StudyGraphics

#VisualAbstract: New-onset atrial fibrillation following hospitalization for pneumonia associated with increased thromboembolic risk

June 28, 2022
Next Post
Initial data on the viability of SARS-CoV-2 in aerosol and on surfaces

Clinical and epidemiologic features of COVID-19 in children

Cognitive outcomes in older adults undergoing cardiovascular procedures unclear

2 Minute Medicine Rewind April 13, 2020

Mycophenolate an effective option for morphea treatment

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Newborn screening for cystic fibrosis improves nutritional outcomes
  • BNT162b2 vaccine reduces rates of COVID-19 omicron variant infection in children
  • Non-contrast CT sensitive and specific for kidney stones [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.